1. Banchereau J, Steinman RM (1998) Dendritic cells and the control of immunity. Nature 392:245–252
2. Lesterhuis WJ, Aarntzen EHJG, Vries IJM, Schuurhuis DH, Figdor CG, Adema GJ, Punt CJA (2008) Dendritic cell vaccines in melanoma: from promise to proof? Crit Rev Oncol Hematol 66:118–134
3. Banchereau J, Palucka AK, Dhodapkar M, Burkeholder S, Taquet N, Rolland A, Taquet S, Coquery S, Wittkowski KM, Bhardwaj N, Pineiro L, Steinman R, Fay J (2001) Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res 61:6451–6458
4. de Vries IJM, Lesterhuis WJ, Scharenborg NM, Engelen LPH, Ruiter DJ, Gerritsen MJP, Croockewit S, Britten CM, Torensma R, Adema GJ, Figdor CG, Punt CJA (2003) Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res 9:5091–5100
5. de Vries IJM, Krooshoop DJEB, Scharenborg NM, Lesterhuis WJ, Diepstra JHS, van Muijen GNP, Strijk SP, Ruers TJ, Boerman OC, Oyen WJG, Adema GJ, Punt CJA, Figdor CG (2003) Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res 63:12–17